Late and Reversible Kidney-Lung Failure after Intra-Bladder BCG Therapy

Olivier Mat1*, Rim Kada1, Patrick Philippart2, Quentin Mat2, Steffy Larroze3, Myriam Remmelink3, Selda Aydin4, Vincent Colombie5

1Department of Nephrology of EpiCURA, Ath, Belgium
2Department of Surgery of EpiCURA, Ath, Belgium
3Department of Lung Pathology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium
4Department of Renal Pathology, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
5Department of Infectious Diseases of EpiCURA, Ath, Belgium

Email: *Olivier.mat@epicura.be

Received May 9, 2013; revised June 15, 2013; accepted July 3, 2013

Copyright © 2013 Olivier Mat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

We observed a 76-year-old man who presented “acute kidney-lung failure” 9 months after intravesical Bacillus Calmette-Guérin (BCG) adjuvant treatment for a T1 bladder cancer. He had inflammatory infiltration on chest radiography and required dialysis for acute renal failure. A percutaneous renal biopsy was performed and revealed tubulointerstitial nephritis with a moderate eosinophilic infiltrate without granulomatous lesion. After a few days, an open lung biopsy was also done due to respiratory deterioration. The anatomopathologic specimen demonstrated moderate fibrosis with lympho-neutrophilic infiltration and few aspecific granulomatous lesions without caseous necrosis. Sarcoïdosis was suspected and high dose oral methylprednisolone was started. Three weeks later, Mycobacterium bovis was identified by Polymerase Chain Reaction on open lung biopsy. He responded well to steroids and tuberculostatic tri-therapy. After one month of immunosuppressive treatment, renal function was resolved and hemodialysis could be discontinued. Despite the frequent use of adjuvant BCG immunotherapy, systemic complications such as hepatitis, pneumonitis, spondylodiscitis or multiorgan failure are rare (<1%). Hematogenous dissemination which occurs a few weeks after traumatic instillations is usually suspected but not demonstrated because of absence of mycobacterium in histological specimen. Our case differs from those previously reported by the simultaneous presence of acid-fast bacilli highlighted on lung samples. We discuss the pathophysiology of BCG complications, the use of prophylactic or therapeutic treatment and recommend guidelines to prevent such complications.

Keywords: Corticosteroids; Hemodialysis; Intravesical BCG; Mycobacterium bovis; Pulmonary Granulomatosis; Renal Failure; Tubulointerstitial Nephritis; Urothelial Carcinoma

1. Introduction

Combined intravesical instillations of BCG remain the gold standard for intermediate and high risk non-invasive urothelial carcinoma of the bladder. Although the appearance of hematuria, dysuria or cystitis is possible, regional or systemic complications are exceptional. The hematogenous spread of mycobacterium from the bladder which occurs a few weeks after traumatic instillations is usually suspected but not demonstrated because of absence of pathogen in histological specimen. Our case correlates tubulointerstitial nephritis to mycobacterial infection by the simultaneous presence of acid-fast bacilli highlighted on lung samples.

2. Case Report

In March 2012, a 76-year-old man was admitted to the hospital because of acute renal failure associated with progressive grade II dyspnea and recurrent low grade fever for 3 weeks. He also reported tiredness, an 8 kg weight loss and night sweats. He had a history of arterial hypertension and a non invasive (T1) transitional cell carcinoma (TCC) of the bladder. TCC was first treated during the second half of 2008 by cauterization followed by mitomycin instillations for 6 months. Because of the recurrence of polyps, the patient was treated by cauterization and one month later, he received 10 intravesical
instillations of Baccile Calmette-Guerin (BCG) between November 2010 and July 2011. Current medications were amlodipine 10 mg and acetylsalicylate 100 mg/day. On admission, physical examination was unremarkable excepted fever of 37.9°C, oliguria and few spread crackles in both lung fields and moderate edema of lower limbs. Regular hemodialysis sessions were initiated based on clinical status and blood sample evaluation.

Laboratory investigation showed hemoglobin 1.2 g/dL, a white blood cell count of $4.6 \times 10^3 /\mu L$ with moderate inflammatory signs (C-reactive protein 30 mg/L, sedimentation rate 30 mm/h), serum creatinine 699 µmol/L. Electrolytes and Lactate deshydrogenase were normal, aspartate aminotransferase 51 IU/L, alcaline phosphatase 208 IU/L and gamma glutamyl transferase 269 IU/L. Total protein count 47.7 g/L with protein electrophoresis demonstrates albumin 25.1 g/L and a thin monoclonal peak of gamma-globulin; the myelogram was normal. Serologic screenings for anti-nuclear antibody, antineutrophil cytoplasmic antibody, anti basal membrane antibody, immunoglobin A and hepatitis B or C antibodies were negative. Plasma complement and coagulation tests were also normal. Angiotensine Converting Enzyme was increased at 140 IU/L (range 8.0 - 52.0) and normal Urine analysis showed proteinuria of 0.4 g/L, sterile leucocyturia without hematuria.

The standard chest X-ray demonstrated a bilateral infiltration of the lung fields. Chest computed tomography confirmed an interstitial syndrome with a “ground glass” appearance associated with small mediastinal lymphadenopathies; there was no pleural effusion, nor micro nodular lesion. Bronchoalveolar lavage was performed and demonstrated no specific lesion; the microscopic examination revealed lympho-monocytic cells with rare neutrophils; mycobacterium culture stayed permanently sterile. A purified protein derivate (PPD) skin test was negative despite a 10 IU dose. Transesophageal cardiac echography excluded infectious endocarditis.

An abdominal CT tomography was performed and demonstrated normal kidneys, no hepatic enlargement and moderate splenomegaly. A percutaneous needle biopsy was performed and revealed tubulointerstitial nephritis with a moderate eosinophilic infiltrate without granulomatous lesion (Figure 1). Glomeruli and arteri-oles appeared normal; there was no histological evidence of rapidly progressive glomerulonephritis. Immunofluorescence was negative and electronic microscopy was unremarkable. After a few days, an open lung biopsy was also done due to respiratory deterioration. The anatomo-pathologic specimen demonstrated moderate fibrosis with lympho-neutrophilic infiltration and few aspecific granulomatous lesions without caseous necrosis or Langhans giant cells (Figure 2). Mycotic identification remained negative. Specific mycobacterium culture was started.

Sarcoidosis was suspected and high dose oral methylprednisolone was started (1 mg/kg/day). The patient’s general condition began to improve after two weeks of corticosteroid therapy in conjunction with intermittent extra-renal epuration and a supportive permanent parenteral nutrition. Fever resolved, weight increased, chest infiltrates disappeared. In the same time, the serum creatinine began to decrease as shown in Figure 3. After one month of immunosuppressive treatment, renal function resolved and hemodialysis could be discontinued. On day 27, culture of lung biopsy samples in Batec 12B medium grew acid-fast bacilli that were identified as Mycobacterium bovis by Polymerase Chain Reaction (Pasteur Institute, Brussels). Cultures of urine, alveolar fluid lavage and blood specimens remained definitely negative. Tuberculostatic agents were promptly initiated as rifadine 600 mg/day, myambutol 1200 mg/2 days, nicotibine 300 mg/day and pyridoxine 250 mg/day. Corticosteroid therapy was gradually reduced and stopped.

Figure 1. Kidney sample.

Figure 2. Lung biopsy.
current immunosuppressive treatment and acute urine radiotherapy treatment, hematuria, active tuberculosis, include recent bladder surgery or polypectomy, recent side effects of BCG instillations [2,3]. Contraindications of suspected BCG toxicity is reported in twelve cases tract infection. Renal failure with histological evidence lactic drug, such as isoniazid, does not seem to reduce which must be considered before instillations. Prophy-
cystitis, cumulative doses are additional risk factors traumatic bladder instillation. Old age, acute bacterial The hematogenous dissemination occurs especially after aneurysms, chorioretinitis and retroperitoneal abscess. tuberculosis, current immunosuppressive treatment and high risk non-invasive urothelial carcinoma of the bladder [1-4]. BCG exerts its antitumor activity through induction of pro-inflammatory cytokines which may explain the flu-like syndrome [4,5] (fever, chills and ar-thralgia) noted in almost 20% of patients receiving therapy. Regional urological complications can occur as mycobacterium orchi-epidydimitis, prostatitis or cystitis. BCG sepsis is a rare (less than 1%, probably due to his high molecular weight) and severe complications with possible multiorgan failure are exceptional [6-9]. Ectopic localizations are also mentioned: hepatitis, pleural ab-scess or pneumonitis, spondylodiscitis, arthritis, mycotic aneurysms, chorioretinitis and retroperitoneal abscess. The hematogenous dissemination occurs especially after traumatic bladder instillation. Old age, acute bacterial cystitis, cumulative doses are additional risk factors which must be considered before instillations. Prophy-
lactic drug, such as isoniazid, does not seem to reduce side effects of BCG instillations [2,3]. Contraindications include recent bladder surgery or polypectomy, recent radiotherapy treatment, hematuria, active tuberculosis, current immunosuppressive treatment and acute urine tract infection. Renal failure with histological evidence of suspected BCG toxicity is reported in twelve cases found by screening the National Library of Medecine’s Medline system. In 9/12 of cases, tubule-interstitial ne-
phritis is presented (5/12 with granuloma) and generally combined with hepatitis; mesangial glomerulonephritis, membranous glomerulonephritis and focal segmental hyalinosis are described as exceptional cases. Mycobacterial infection are usually considered as suspected responsible pathogen but not demonstrated because of absence of mycobacterium in histological specimen. Our case differs from those previously reported by the simult-
aneous presence of acid-fast bacilli highlighted on lung samples. The evidence of Mycobacterium bovis by DNA-
rNA hybridization strengthens the temporal relationship between BCG instillations and kidney-lung impairment despite the unusual delayed onset complications since generally occurring a few weeks after the last instillation [5-7]. Some authors stratified into early- and late-presen-
tation disease [10]. The first one (within 3 months) could be result from systemic infection with proliferation of the organisms causing generalized granulomatous re-
sponse by repeated instillations. The second one (be-
tween 3 months and until more than 1 year) could result from reactivation of infection after successful immu-
nologic control of early dissemination, which is rather the case of our patient. Despite severe presentation of “BCGitis”, corticosteroids administration often results in a prompt recovery of both renal and lung functions. The role of corticosteroids in the treatment of the complications of BCG instillations is not clearly defined within randomized studies. Nevertheless, their use seems interest-
ing since the objective of BCG instillation is to induce immune reaction of the host and so we can assume that symptoms may be at least partially related to this me-
chanism. In the present case, positive culture for Myco-
bacterium bovis questioned the only hypothesis of hy-
persensitivity reaction, reason why tuberculostatic drugs were added to corticosteroids. We also noted that, despite the absence of tuberculostatic agents during the initial phase of treatment, no proven dissemination of myco-
bacteria occurred.

4. Conclusion

Unusual complications due to adjuvant BCG immuno-
therapy mostly occur a few weeks after intravesical treat-
ment. Prevention of these adverse events requires avoiding the risk factors (recent bladder surgery or poly-
tomy, recent radiotherapy treatment, hematuria, active tuberculosis, current immunosuppressive treatment and acute urinary tract infection) and regular control of renal function during prolonged therapy. Treatment by corticosteroids improves the outcome of patients and the question of tuberculostatic therapy should always be con-
sidered. Prophylactic drug, such as isoniazid, does not seem to prevent side effects of BCG instillations.

REFERENCES


Figure 3. Recovery of renal function under corticosteroid therapy.

The patient is in good condition 6 months after initiation of antituberculosis therapy; chronic renal failure persisted with a serum creatinine of 220 μmol/L.

3. Discussion

Intravesical immunotherapy with BCG has been safely used to treat recurrence of superficial transitional cell carcinoma of the bladder for more than thirty years and remains a cornerstone for the treatment of intermediate and high risk non-invasive urothelial carcinoma of the bladder [1-4]. BCG exerts its antitumor activity through induction of pro-inflammatory cytokines which may explain the flu-like syndrome [4,5] (fever, chills and ar-thralgia) noted in almost 20% of patients receiving therapy. Regional urological complications can occur as mycobacterium orchi-epidydimitis, prostatitis or cystitis. BCG sepsis is a rare (less than 1%, probably due to his high molecular weight) and severe complications with possible multiorgan failure are exceptional [6-9]. Ectopic localizations are also mentioned: hepatitis, pleural ab-scess or pneumonitis, spondylodiscitis, arthritis, mycotic aneurysms, chorioretinitis and retroperitoneal abscess.


